Karolinska Development AB (publ) (KDEV.ST)
SEK 0.85
(-0.47%)
SEK 0.85
(-0.47%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -26.78 Million SEK | 96.25% |
| 2022 | -87.99 Million SEK | -157.59% |
| 2021 | -27.92 Million SEK | 60.01% |
| 2020 | -201.73 Million SEK | 43.57% |
| 2019 | -38.27 Million SEK | -155.18% |
| 2018 | 79.97 Million SEK | 36.42% |
| 2017 | 223.09 Million SEK | -26.72% |
| 2016 | -217.78 Million SEK | 28.36% |
| 2015 | -1.05 Billion SEK | 46.14% |
| 2014 | -371.27 Million SEK | 32.03% |
| 2013 | -94.66 Million SEK | 40.58% |
| 2012 | -161.85 Million SEK | 60.39% |
| 2011 | 3.43 Million SEK | -28.97% |
| 2010 | -311.84 Million SEK | -26621.59% |
| 2009 | -1.16 Million SEK | 74.5% |
| 2008 | -4.57 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.27 Million SEK | -10.33% |
| 2024 Q2 | -17.26 Million SEK | -1.44% |
| 2023 FY | - SEK | 96.25% |
| 2023 Q4 | -4.06 Million SEK | 77.31% |
| 2023 Q3 | -17.92 Million SEK | 52.5% |
| 2023 Q1 | 15.36 Million SEK | 119.69% |
| 2023 Q2 | -37.73 Million SEK | -345.55% |
| 2022 Q4 | -78.05 Million SEK | -312.89% |
| 2022 Q2 | 5.18 Million SEK | -20.77% |
| 2022 Q1 | 6.53 Million SEK | -96.86% |
| 2022 FY | - SEK | -157.59% |
| 2022 Q3 | 36.66 Million SEK | 607.78% |
| 2021 Q3 | -9.11 Million SEK | 95.87% |
| 2021 Q2 | -220.81 Million SEK | -2227.47% |
| 2021 Q4 | 208.02 Million SEK | 2383.21% |
| 2021 FY | - SEK | 60.01% |
| 2021 Q1 | 10.37 Million SEK | 103.84% |
| 2020 Q1 | 112.3 Million SEK | 708.9% |
| 2020 FY | - SEK | 43.57% |
| 2020 Q3 | 150.89 Million SEK | 804.8% |
| 2020 Q4 | -270.6 Million SEK | -279.33% |
| 2020 Q2 | -21.41 Million SEK | -119.06% |
| 2019 Q2 | -40.69 Million SEK | -231.98% |
| 2019 Q4 | 13.88 Million SEK | 215.83% |
| 2019 FY | - SEK | -155.18% |
| 2019 Q3 | -11.98 Million SEK | 70.54% |
| 2019 Q1 | -12.25 Million SEK | -118.21% |
| 2018 Q3 | -26.27 Million SEK | 50.3% |
| 2018 Q1 | -8.17 Million SEK | -104.18% |
| 2018 FY | - SEK | 36.42% |
| 2018 Q4 | 67.3 Million SEK | 356.17% |
| 2018 Q2 | -52.86 Million SEK | -546.84% |
| 2017 Q1 | -1.83 Million SEK | 98.73% |
| 2017 Q4 | 195.38 Million SEK | 188.57% |
| 2017 Q2 | -4.41 Million SEK | -140.69% |
| 2017 FY | - SEK | -26.72% |
| 2017 Q3 | -220.59 Million SEK | -4891.9% |
| 2016 Q1 | 74.48 Million SEK | 108.47% |
| 2016 FY | - SEK | 28.36% |
| 2016 Q3 | -7.81 Million SEK | -114.77% |
| 2016 Q4 | -144.4 Million SEK | -1748.92% |
| 2016 Q2 | 52.89 Million SEK | -28.99% |
| 2015 Q3 | 5.42 Million SEK | -99.13% |
| 2015 FY | - SEK | 46.14% |
| 2015 Q1 | 239.57 Million SEK | 176.95% |
| 2015 Q2 | 624.04 Million SEK | 160.48% |
| 2015 Q4 | -879.53 Million SEK | -16324.59% |
| 2014 Q2 | 163.37 Million SEK | 2404.95% |
| 2014 FY | - SEK | 32.03% |
| 2014 Q4 | -311.32 Million SEK | -443.27% |
| 2014 Q3 | 90.69 Million SEK | -44.49% |
| 2014 Q1 | -7.08 Million SEK | -101.93% |
| 2013 Q4 | 367.66 Million SEK | 597.29% |
| 2013 Q3 | 52.72 Million SEK | 206.62% |
| 2013 Q2 | -49.45 Million SEK | 89.38% |
| 2013 FY | - SEK | 40.58% |
| 2013 Q1 | -465.61 Million SEK | -872.66% |
| 2012 Q2 | -44.81 Million SEK | 52.42% |
| 2012 Q1 | -94.18 Million SEK | 68.07% |
| 2012 Q4 | -47.87 Million SEK | -35.88% |
| 2012 Q3 | -35.23 Million SEK | 21.38% |
| 2012 FY | - SEK | 60.39% |
| 2011 Q1 | -41.21 Million SEK | 0.0% |
| 2011 Q4 | -294.96 Million SEK | -861.52% |
| 2011 FY | - SEK | -28.97% |
| 2011 Q2 | -45.1 Million SEK | -9.44% |
| 2011 Q3 | -30.67 Million SEK | 31.99% |
| 2010 FY | - SEK | -26621.59% |
| 2010 Q3 | - SEK | 0.0% |
| 2009 FY | - SEK | 74.5% |
| 2008 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 92.718% |
| AcouSort AB (publ) | -16.7 Million SEK | -60.348% |
| Active Biotech AB (publ) | -43.88 Million SEK | 38.973% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 63870.566% |
| Amniotics AB (publ) | -27.14 Million SEK | 1.326% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -88.387% |
| BioArctic AB (publ) | 275.38 Million SEK | 109.726% |
| Camurus AB (publ) | 562.54 Million SEK | 104.761% |
| Cantargia AB (publ) | -284.31 Million SEK | 90.58% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -36.795% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -56.768% |
| Genovis AB (publ.) | 64.57 Million SEK | 141.478% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 76.692% |
| Mendus AB (publ) | -97.84 Million SEK | 72.627% |
| Kancera AB (publ) | -61.88 Million SEK | 56.724% |
| LIDDS AB (publ) | -39.67 Million SEK | 32.486% |
| Lipum AB (publ) | -37.11 Million SEK | 27.846% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -121.274% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 185.285% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 1339250.0% |
| NextCell Pharma AB | -40.98 Million SEK | 34.652% |
| OncoZenge AB (publ) | 7.26 Million SEK | 468.607% |
| Saniona AB (publ) | -69.69 Million SEK | 61.571% |
| Simris Alg AB (publ) | -22.36 Million SEK | -19.765% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 91.564% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 90.504% |
| Xintela AB (publ) | -53.47 Million SEK | 49.911% |
| Ziccum AB (publ) | -20.34 Million SEK | -31.664% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 27.66% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 84.228% |
| CombiGene AB (publ) | -35.33 Million SEK | 24.205% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 80.985% |
| Intervacc AB (publ) | -68.98 Million SEK | 61.173% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 88.728% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -1187.644% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -99.412% |
| Corline Biomedical AB | -1.69 Million SEK | -1483.856% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 84.547% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 51.131% |
| Aptahem AB (publ) | -10 Million SEK | -167.583% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 331.908% |
| Fluicell AB (publ) | -25.91 Million SEK | -3.353% |
| Biovica International AB (publ) | -119.5 Million SEK | 77.589% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 36.569% |
| Abliva AB (publ) | -93.6 Million SEK | 71.388% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 91.607% |
| 2cureX AB (publ) | -35.13 Million SEK | 23.773% |
| I-Tech AB | 30.34 Million SEK | 188.262% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 96.252% |
| Cyxone AB (publ) | -20.41 Million SEK | -31.199% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 73.858% |
| Biosergen AB | 228 Thousand SEK | 11846.93% |
| Nanologica AB (publ) | -62.11 Million SEK | 56.884% |
| SynAct Pharma AB | -222.7 Million SEK | 87.974% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 38.937% |
| BioInvent International AB (publ) | -312.7 Million SEK | 91.435% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 8756.068% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 88.437% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -203.921% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 75.328% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -133.525% |